Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. - Wikidata - awgldk - TriplyDB

Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.

Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.

http://www.wikidata.org/entity/Q41905507

about

Recent advances in the molecular understanding of glioblastoma NETRIN-4 protects glioblastoma cells FROM temozolomide induced senescence A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells.Seizure prognosis in brain tumors: new insights and evidence-based management A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Levetiracetam improves verbal memory in high-grade glioma patients.Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications.The role of levetiracetam in treatment of seizures in brain tumor patients.Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.Epilepsy in the cancer patient.An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools.Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment.Why dapsone stops seizures and may stop neutrophils' delivery of VEGF to glioblastoma.The strategy for enhancing temozolomide against malignant glioma.Optimizing antiepileptic drug treatment in tumoral epilepsy.Treatment of epileptic seizures in brain tumors: a critical review.Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics.Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.The withdrawal of antiepileptic drugs in patients with low-grade and anaplastic glioma.Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.Neurobehavioral effects of levetiracetam in brain tumor related epilepsy.Prognostic relevance of epilepsy at presentation in glioblastoma patients Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.Pharmacological effects of asiatic acid in glioblastoma cells under hypoxia.Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam Anti-convulsants and gene expression in malignant gliomas.Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.Drug Repositioning in Glioblastoma: A Pathway Perspective.Investigating the role of Hedgehog/GLI1 signaling in glioblastoma cell response to temozolomide.Recent innovations in the management of low-grade gliomas.

P2860

Q24632928-12056238-0694-400B-A5BC-AB6C29028293 Q28535039-FB64C9E9-2624-497B-A07B-05D57451D4D3 Q30412393-C265BB3C-2E9C-4AA1-84A5-70149285757E Q33400189-5A0611EA-C9CA-4507-AE1A-F95426D012A5 Q33746514-0B469D14-69FA-4791-9397-85A2BB8AF6A5 Q33768138-A3112C6D-4B99-493F-BB1A-54639D9E594B Q33829789-7AB29CFE-7C50-4607-88FD-9DA28B7757EB Q35088396-76DFA015-D9A4-42D8-9D55-1694E813C140 Q35785924-3176EAE9-8A7F-4014-ABA1-48BF1396F272 Q36283445-3B88DA43-9195-427F-B551-24C80E1E4A13 Q36299167-46A6232C-7BA9-4879-8601-5DA3EDCFAD1B Q36544087-8805AB48-9EEC-400F-B676-726A8B8E07F1 Q36893208-D9494830-725C-40E3-9788-024103041594 Q36909520-6050CB3B-3ED0-4017-AD84-A45F60A9DBED Q37217443-6E93CCFF-1F64-4CD9-B3C9-7DE81DC360E6 Q37350851-F8A108A4-9E5B-4864-90A1-78CCCDDAF591 Q37838314-DBADE753-3C96-4893-BD47-FA2B3468F92F Q37858468-04E4DA10-D8CD-47C3-A977-40FC24DD4788 Q37861732-6B2E8EF8-DF6F-4341-9154-616769394E2D Q37968607-6A52BED2-9A90-4584-95DD-52496B88C331 Q38007011-351D7181-283B-4940-9B65-7E9E617A6031 Q38036657-26F4654C-9952-4698-89E5-92CABC4DB9AF Q38170433-27156BD3-CFB4-4B22-B92B-881A4E9BD45D Q38206723-CAFB9780-D8B9-4277-8CB1-283C6189E54C Q38225830-B26D3EA3-3B22-4747-A5E2-000533038ED8 Q38495389-89A9A141-0841-4B02-B082-5519098EEE5C Q38587724-36FFDABB-9CEB-43DD-B9E2-D83AF3F939FA Q38916416-7C78A1D4-28D6-4C6C-9767-C44E2C7850ED Q39162666-12B4E06A-F56D-4815-8CB7-92F029CD6C78 Q39378541-1E33BC9B-0170-424B-B691-1B10EA69C061 Q40016347-057452B8-1BB9-4F2D-ADD6-B7D3517FBE44 Q41738194-EF4845BB-9877-4551-80C9-177795F8EFB9 Q42029615-150CCCFE-2767-428E-A4B6-3315D3E0691C Q42330282-A708BE73-DC2B-4A44-A111-0D8FC2B95FD2 Q42792502-0A2094BD-A505-4E6B-9559-672343B30A1C Q47949323-BC439F92-D4C6-4305-8E3B-D1067F7831E9 Q48873373-CFEFBB20-63BE-45A8-8F26-E536DDB7D262 Q52608766-A26D2C9F-0F84-47BB-87EB-70BACDABFF9A Q55327757-CC019E3A-FA16-4C23-84F2-1D5273002710 Q55462054-415E6087-F013-4A7E-A72B-C90ECD0D2E64

P2860

Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.

http://www.wikidata.org/entity/Q41905507

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Levetiracetam enhances p53-med ...... lastoma cells to temozolomide.

@en

type

label

Levetiracetam enhances p53-med ...... lastoma cells to temozolomide.

@en

prefLabel

Levetiracetam enhances p53-med ...... lastoma cells to temozolomide.

@en

P1433

Q41905507-84F1E188-C8BF-41C1-8BCB-D9FC1E0BC932

P1476

Q41905507-BF08B7A4-2624-4745-BC67-1604ED067FC8

P2093

Q41905507-16583E64-1FD3-4F3B-9F05-6A1BE2A05B1F

Q41905507-4E6EBB4A-BD4C-4833-AEF1-9E502A7C6124

Q41905507-60BC04A9-DB8D-4FE6-AE40-3EEA90B98786

Q41905507-928945C9-417C-4B27-926C-808F3D55E59B

Q41905507-C04D6420-D213-4ABC-A5F6-B5B3E1E3DF99

Q41905507-CBF3B1C4-D45A-4211-A77A-C3FBD9C31F0B

Q41905507-E0B839C2-BE2D-47C8-85BD-F753E1B0371E

P2860

Q41905507-02A70F88-0558-4B58-A25A-4036F0F2ECB6

Q41905507-0CE2D137-0150-4483-A7FE-2477A79797AF

Q41905507-0F0B9ECB-8996-45C6-97B3-E88E4707B24E

Q41905507-1D908121-7872-4E55-AEAD-3AD1544F7F2B

Q41905507-2050B5FF-3E4E-49FA-8D58-A22F184B0C2C

Q41905507-25A1063C-8368-4D96-9BA2-E5E9047769E7

Q41905507-2B6622F5-2E57-421D-800A-98A53CD7673C

Q41905507-32DB2152-2E2E-4232-88C2-EA7464D1AF89

Q41905507-4208334B-0BBF-4917-8E13-3ECA72525CA8

Q41905507-47E79EE5-8DA4-4C64-A983-BBE29C8427A1

P304

Q41905507-E1086DA8-3F1E-491C-A33E-C9B85A63C245

P31

Q41905507-29E5BAF8-62F1-4B9A-BDA0-0000F32321F0

P356

Q41905507-AC6D8D1B-152B-4CB6-8801-1417E32B2F6D

P433

Q41905507-2D911C65-FB22-4B7C-A166-89B497553200

P478

Q41905507-15D01538-E9DA-44F5-B9BA-132C305CECDF

P577

Q41905507-B141A00E-D198-4005-8DE5-3183B1036CFE

P5875

Q41905507-172D04BB-EDF2-454C-9084-AAEC8CBED616

P698

Q41905507-C2B2380F-7812-4634-B3EC-9B3D7E86D3C3

P932

Q41905507-15FD5BAA-C801-49C2-9A63-F6FB8BD6E5E1

P356

P1433

P1476

Levetiracetam enhances p53-med ...... lastoma cells to temozolomide.

@en

P2093

Arati Limaye

http://www.w3.org/2001/XMLSchema#string

Cheryl H Baker

http://www.w3.org/2001/XMLSchema#string

Gary Pearl

http://www.w3.org/2001/XMLSchema#string

George C Bobustuc

http://www.w3.org/2001/XMLSchema#string

Nicholas G Avgeropoulos

http://www.w3.org/2001/XMLSchema#string

Santhi D Konduri

http://www.w3.org/2001/XMLSchema#string

Wayne D Jenkins

http://www.w3.org/2001/XMLSchema#string

P2860

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule

p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents

Repair of O(6)-alkylguanine by alkyltransferases.

Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies.

Malignant gliomas.

The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.

Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a.

DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas

P304

917-927

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOQ044

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44651731

http://www.w3.org/2001/XMLSchema#string

P698

20525765

http://www.w3.org/2001/XMLSchema#string

P932

2940696

http://www.w3.org/2001/XMLSchema#string